Real-world evidence: benefits and business cases
This article is part one of a two-part series.
National & patient surveys
Electronic medical & health records
Lab values / Biomarkers
Data aggregates by therapeutic area: Optum, Symphony, etc.
Commercial Pharma data aggregates: MarketScan, etc.
In Summary, the RWE data across the different healthcare eco-system pockets is truly a value multiplier for a pharmaceutical company enabling it to stay competitive & relevant in the constantly evolving healthcare market and realize a $1B business case. With that, please do stay tuned for Part 2 of this article in which my colleagues and I will explain how to build a competitive RWE Analytics Platform also addressing the critical Life Sciences & Regulatory topics such as HIPPA, GxP, Data Anonymization, to name a few.